Market Spotlight: Basal Cell Carcinoma
Market Spotlight: Basal Cell Carcinoma
This Market Spotlight report covers the basal cell carcinoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
This Market Spotlight report covers the basal cell carcinoma market, comprising key marketed and pipeline drugs, epidemiology, clinical trials, upcoming events, probability of success, patent information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- The approved drugs in the basal cell carcinoma space target the immune system, reactive oxygen species, free radicals, thymidylate synthase, and hedgehog signaling pathway. The majority of these therapies are administered via the topical route, with the remainder being oral formulations.
- The majority of industry-sponsored drugs in active clinical development for basal cell carcinoma are in Phase II, with one drug in Phase III.
- Therapies in the pipeline for basal cell carcinoma focus on a wide variety of targets. These drugs are administered via the topical, oral, intravenous, and intratumoral routes.
- High-impact upcoming events for drugs in the basal cell carcinoma space comprise topline Phase II trial results for Libtayo, and topline Phase III trial results for Ameluz.
- The overall likelihood of approval of a Phase I solid tumor asset is 5.7%, and the average probability a drug advances from Phase III is 39.4%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.2 years in the overall oncology space.
- There have been seven licensing and asset acquisition activities involving basal cell carcinoma drugs during 2013–18. The $175m agreement between Sun Pharmaceutical and Novartis in December 2016, for the acquisition of Novartis’s branded oncology product, Odomzo, by Sun Pharmaceutical, was the largest deal during the period.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for basal cell carcinoma have been in the early and mid-phases of development, with 81% of trials in Phase I–II, and only 19% in Phase III–IV.
- The US has a substantial lead in the number of basal cell carcinoma clinical trials globally, while the UK leads the major EU markets.
- Clinical trial activity in the basal cell carcinoma space is dominated by completed trials. Roche and Bausch Health have the highest number of completed clinical trials for basal cell carcinoma, with 15 and 14 trials, respectively.
- Roche leads industry sponsors with the highest number of clinical trials for basal cell carcinoma, followed by Novartis and Bausch Health.
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Basal cell carcinoma subtypes
9 Electrodesiccation and curettage (ED&C)
9 Mohs micrographic surgery
9 Excisional surgery
9 Radiation therapy
10 Photodynamic therapy (PDT)
10 Laser surgery
10 Medical therapies
12 Recent incidence studies
13 MARKETED DRUGS
15 Approvals by country
18 PIPELINE DRUGS
24 KEY UPCOMING EVENTS
25 PROBABILITY OF SUCCESS
26 LICENSING AND ASSET ACQUISITION DEALS
26 Sun Acquires Novartis Cancer Drug In Specialty Push
27 PARENT PATENTS
28 REVENUE OPPORTUNITY
29 CLINICAL TRIAL LANDSCAPE
30 Sponsors by status
31 Sponsors by phase
32 Recent events
33 Prescription information
LIST OF FIGURES
18 Figure 1: Overview of pipeline drugs for basal cell carcinoma in the US
19 Figure 2: Pipeline drugs for basal cell carcinoma, by company
19 Figure 3: Pipeline drugs for basal cell carcinoma, by drug type
19 Figure 4: Pipeline drugs for basal cell carcinoma, by classifications
24 Figure 5: Key upcoming events in basal cell carcinoma
25 Figure 6: Probability of success in the basal cell carcinoma pipeline
26 Figure 7: Licensing and asset acquisition deals in basal cell carcinoma, 2013–18
27 Figure 8: Parent patents in basal cell carcinoma
29 Figure 9: Clinical trials in basal cell carcinoma
29 Figure 10: Top 10 drugs for clinical trials in basal cell carcinoma
30 Figure 11: Top 10 companies for clinical trials in basal cell carcinoma
30 Figure 12: Trial locations in basal cell carcinoma
31 Figure 13: Basal cell carcinoma trials status
32 Figure 14: Basal cell carcinoma trials sponsors, by phase
LIST OF TABLES
14 Table 1: Marketed drugs for basal cell carcinoma
16 Table 2: Approvals by country for basal cell carcinoma
21 Table 3: Pipeline drugs for basal cell carcinoma in the US
28 Table 4: Historical global sales, by drug ($m), 2013–17
28 Table 5: Forecasted global sales, by drug ($m), 2018–22
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email firstname.lastname@example.org for further help or assistance.